Le Lézard
Classified in: Health, Business
Subject: SHAREHOLDER RIGHTS PLANS

BioSyent Announces Grant of Restricted Share Units


MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent" or the "Company", TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units "RSUs" to certain directors, officers, management, and employees of the Company pursuant to the Company's Restricted Share Unit Plan (the "RSU Plan"). These RSUs will fully vest within three years on the third anniversary of the applicable grant date.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,616,492 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.



These press releases may also interest you

at 03:30
SpliceBio, a genetic medicines company pioneering Protein...

at 03:30
General Inception, a global biotech...

at 03:30
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development...

at 03:30
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the...

at 03:25
Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that...

at 03:04
From December 1st to 5th, 2024, RSNA 2024?the largest and most future-oriented top medical event in the global radiology community, was held in Chicago. At this conference, Careverse officially made its debut, exhibiting in the AI Showcase area,...



News published on and distributed by: